Title: Hyperdiploidy with 58-66 chromosomes in childhood B-acute lymphoblastic leukemia is highly curable: 58951 CLG-EORTC results
Authors: Dastugue, Nicole ×
Suciu, Stefan
Plat, Geneviève
Speleman, Frank
Cavé, Hélène
Girard, Sandrine
Bakkus, Marleen
Pagès, Marie Pierre
Yakouben, Karima
Nelken, Brigitte
Uyttebroeck, Anne
Gervais, Carine
Lutz, Patrick
Teixeira, Manuel R
Heimann, Pierre
Ferster, Alice
Rohrlich, Pierre
Collonge, Marie Agnès
Munzer, Martine
Luquet, Isabelle
Boutard, Patrick
Sirvent, Nicolas
Karrasch, Matthias
Bertrand, Yves
Benoit, Yves #
Issue Date: Mar-2013
Publisher: W.B. Saunders
Series Title: Blood vol:121 issue:13 pages:2415-23
Article number: 10.1182/blood-2012-06-437681
Abstract: The aim of our study was to analyze the factors contributing to heterogeneity of prognosis in patients with hyperdiploidy>50 chromosomes (HD>50), a group of B-cell precursor acute lymphoblastic leukemia with favorable outcome. The 541 HD>50 patients registered prospectively in the 58951 European Organisation for Research and Treatment of Cancer (EORTC) Children's Leukemia Group (CLG) trial, identified by karyotype (446 patients) and by DNA index (DI) (490 patients), had a 6-year event-free survival (EFS) of 89.0% (standard error [SE] = 1.5%) and a 6-year overall survival (OS) of 95.9% (SE = 0.9%). The strongest prognostic factor was the modal number of chromosomes (MNC): the 6-year EFS of 51-53, 54-57, and 58-66 MNC groups were 80%, 89%, and 99%, respectively (P < .0001). Ploidy assessed by DI was also a favorable factor: the higher the DI, the better the outcome. The 6-year EFS of the 3 subgroups of DI < 1.16/≥1.16-<1.24/≥1.24 were 83%, 90%, and 95%, respectively (P = .009). All usual combinations of trisomies (chromosomes 4, 10, 17, 18) were significant favorable factors but had lower EFS when MNC was lower than 58. In multivariate analysis, MNC remained the strongest factor. Consequently, the best indicator for excellent outcome was ploidy assessed by karyotype because patients with 58-66 chromosomes stood every chance of being cured (OS of 100% at 6-year follow-up) with less-intensive therapy. This trial was registered at as #NCT00003728. Registered:,
ISSN: 0006-4971
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Organ Systems (+)
× corresponding author
# (joint) last author

Files in This Item:

There are no files associated with this item.

Request a copy


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science